Compare ASLE & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASLE | IRWD |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.0M | 251.8M |
| IPO Year | N/A | 2010 |
| Metric | ASLE | IRWD |
|---|---|---|
| Price | $6.95 | $3.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $7.00 | $5.34 |
| AVG Volume (30 Days) | 417.3K | ★ 2.3M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.11 | ★ 0.18 |
| Revenue | ★ $339,090,000.00 | $338,987,000.00 |
| Revenue This Year | $1.35 | N/A |
| Revenue Next Year | $19.09 | $4.01 |
| P/E Ratio | $62.29 | ★ $20.22 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.56 | $0.53 |
| 52 Week High | $9.12 | $5.13 |
| Indicator | ASLE | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 61.99 |
| Support Level | $6.33 | $3.50 |
| Resistance Level | $7.11 | $3.80 |
| Average True Range (ATR) | 0.16 | 0.33 |
| MACD | 0.11 | -0.05 |
| Stochastic Oscillator | 82.50 | 58.96 |
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.